Cytokines and hs-CRP levels in individuals treated with low-dose aspirin a Cross Mark for cardiovascular prevention: A population-based study (CoLaus Study)

被引：23
作者：
Vaucher, Julien [1 ,2 ]
Marques-Vidal, Pedro [2 ,3 ]
Waeber, Gerard [1 ,2 ]
Vollenweider, Peter [1 ,2 ]
机构：
[1] CHU Vaudois, Dept Med, Lausanne, Switzerland
[2] Fac Biol & Med, Lausanne, Switzerland
[3] CHU Vaudois, Inst Social & Prevent Med IUMSP, Lausanne, Switzerland
来源：
CYTOKINE | 2014年 / 66卷 / 02期
基金：
瑞士国家科学基金会;
关键词：
Cytokines; hs-CRP; Low-dose aspirin; Cardiovascular prevention; Population-based sample; C-REACTIVE PROTEIN; CHRONIC STABLE ANGINA; INFLAMMATORY MARKERS; EUROPEAN-SOCIETY; TASK-FORCE; KAPPA-B; DISEASE; GUIDELINES; RISK; ATHEROSCLEROSIS;
D O I：
10.1016/j.cyto.2014.01.003
中图分类号：
Q5 [生物化学]; Q7 [分子生物学];
学科分类号：
071010 ; 081704 ;
摘要：
Pro-inflammatory cytokines and high-sensitive C-reactive protein (hs-CRP) are associated with increased risk for cardiovascular disease. Low-dose aspirin for CV prevention is reported to have anti-inflammatory effects. The aim of this study was to determine the association between pro-inflammatory cytokines and hs-CRP levels and low-dose aspirin use for cardiovascular prevention in a population-based cohort (CoLaus Study). We assessed blood samples in 6085 participants (3201 women) aged 35-75 years. Medications' use and indications were recorded. Among aspirin users (n = 1'034; 17%), overall low-dose users (351; 5.8%) and low-dose for cardiovascular prevention users (324; 5.3%) were selected for analysis. Pro-inflammatory cytokines (IL-1 beta, IL-6 and TNF-alpha were assessed by a multiplex particle-based flow cytometric assay and hs-CRP by an immunometric assay. Cytokines and hs-CRP were presented in quartiles. Multivariate analysis adjusting for sex, age, smoking status, body mass index, diabetes mellitus and immunomodulatory drugs showed no association between cytokines and hs-CRP levels and low-dose aspirin use for cardiovascular prevention, either comparing the topmost vs. the three other quartiles (OR 95% CI, 0.84 (0.59-1.18), 1.03 (0.78-1.32), 1.10 (0.83-1.46), 1.00 (0.67-1.69) for IL-1 beta, IL-6, TNF-alpha and hs-CRP, respectively), or comparing the topmost quartile vs. the first one (OR 95% CI, 0.87 (0.60-1.26), 1.19 (0.79-1.79), 1.26 (0.86-1.84), 1.06 (0.67-1.69)). Low-dose aspirin use for cardiovascular prevention does not impact plasma pro-inflammatory cytokine and hs-CRP levels in a population-based cohort. (C) 2014 Elsevier Ltd. All rights reserved.
引用
收藏
页码：95 / 100
页数：6
相关论文
共 44 条
[11]   Validation and comparison of luminex multiplex cytokine analysis kits with ELISA: Determinations of a panel of nine cytokines in clinical sample culture supernatants [J].
duPont, NC ;
Wang, KH ;
Wadhwa, PD ;
Culhane, JF ;
Nelson, EL .
JOURNAL OF REPRODUCTIVE IMMUNOLOGY, 2005, 66 (02) :175-191
[12]   Effects of low-dose aspirin on serum C-reactive protein and thromboxane B2 concentrations:: A placebo-controlled study using a highly sensitive C-reactive protein assay [J].
Feldman, M ;
Jialal, I ;
Devaraj, S ;
Cryer, B .
JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, 2001, 37 (08) :2036-2041
[13]   Effect of short-term aspirin use on C-reactive protein [J].
Feng, DL ;
Tracy, RP ;
Lipinska, I ;
Murillo, J ;
McKenna, C ;
Tofler, GH .
JOURNAL OF THROMBOSIS AND THROMBOLYSIS, 2000, 9 (01) :37-41
[14]   The CoLaus study: a population-based study to investigate the epidemiology and genetic determinants of cardiovascular risk factors and metabolic syndrome [J].
Firmann, Mathieu ;
Mayor, Vladimir ;
Vidal, Pedro Marques ;
Bochud, Murielle ;
Pecoud, Alain ;
Hayoz, Daniel ;
Paccaud, Fred ;
Preisig, Martin ;
Song, Kijoung S. ;
Yuan, Xin ;
Danoff, Theodore M. ;
Stirnadel, Heide A. ;
Waterworth, Dawn ;
Mooser, Vincent ;
Waeber, Gerard ;
Vollenweider, Peter .
BMC CARDIOVASCULAR DISORDERS, 2008, 8 (1)
[15]   Mechanisms of disease: Toll-like receptors in cardiovascular disease [J].
Frantz, Stefan ;
Ertl, Georg ;
Bauersachs, Johann .
NATURE CLINICAL PRACTICE CARDIOVASCULAR MEDICINE, 2007, 4 (08) :444-454
[16]   Efficacy of different doses of aspirin in decreasing blood levels of inflammatory markers in patients with cardiovascular metabolic syndrome [J].
Gao, Xiu-ren ;
Adhikari, Chandar M. ;
Peng, Long-yun ;
Guo, Xiao-gang ;
Zhai, Yuan-sheng ;
He, Xu-yu ;
Zhang, Li-Yuan ;
Lin, Jun ;
Zuo, Zhi-yi .
JOURNAL OF PHARMACY AND PHARMACOLOGY, 2009, 61 (11) :1505-1510
[17]   Rosuvastatin for Primary Prevention in Older Persons With Elevated C-Reactive Protein and Low to Average Low-Density Lipoprotein Cholesterol Levels: Exploratory Analysis of a Randomized Trial [J].
Glynn, Robert J. ;
Koenig, Wolfgang ;
Nordestgaard, Borge G. ;
Shepherd, James ;
Ridker, Paul M. .
ANNALS OF INTERNAL MEDICINE, 2010, 152 (08) :488-U31
[18]   European guidelines on cardiovascular disease prevention in clinical practice: Full text [J].
Graham, Ian ;
Atar, Dan ;
Borch-Johnsen, Knut ;
Boysen, Gudrun ;
Burell, Gunilla ;
Cifkova, Renata ;
Dallongeville, Jean ;
De Backer, Guy ;
Ebrahim, Shah ;
Gjelsvik, Bjorn ;
Herrmann-Lingen, Christoph ;
Hoes, Arno ;
Humphries, Steve ;
Knapton, Mike ;
Perk, Joep ;
Priori, Silvia G. ;
Pyorala, Kalevi ;
Reiner, Zeljko ;
Ruilope, Luis ;
Sans-Menendez, Susana ;
Reimer, Wilma Scholte Op ;
Weissbergh, Peter ;
Wood, David ;
Yarnell, John ;
Zamorano, Jose Luis .
EUROPEAN JOURNAL OF CARDIOVASCULAR PREVENTION & REHABILITATION, 2007, 14 :S1-S113
[19]   Lipoxin (LX)A4 and aspirin-triggered 15-epi-LXA4 inhibit tumor necrosis factor 1α-initiated neutrophil responses and trafficking:: Regulators of a cytokine-chemokine axis [J].
Hachicha, M ;
Pouliot, M ;
Petasis, NA ;
Serhan, CN .
JOURNAL OF EXPERIMENTAL MEDICINE, 1999, 189 (12) :1923-1929
[20]   Effects of aspirin on serum C-reactive protein and interleukin-6 levels in patients with type 2 diabetes without cardiovascular disease:: a randomized placebo-controlled crossover trial [J].
Hovens, M. M. C. ;
Snoep, J. D. ;
Groeneveld, Y. ;
Froelich, M. ;
Tamsma, J. T. ;
Huisman, M. V. .
DIABETES OBESITY & METABOLISM, 2008, 10 (08) :668-674
12345